AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15200753 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/acetaminophen (multidose regimen)
Number of subjects: 271
Study 15200753 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/acetaminophen
Number of subjects: 271
Study 15200753 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 271
Study 15200753 — intervention group
Group type: COMPARATOR
Intervention: Active treatment (Rofecoxib or Oxycodone/acetaminophen)
Number of subjects: 271
Study 11506104 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-training group (n = 12)
Number of subjects: 24
Study 11506104 — intervention group
Group type: COMPARATOR
Intervention: Didactic-teaching group (n = 12)
Number of subjects: 24
Study 9601649 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ end-labelling (ISEL) for detecting apoptotic cells
Number of subjects: 0
Study 9601649 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry for PARP
Number of subjects: 0
Study 9601649 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry for Ku80
Number of subjects: 0
Study 7721516 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of physical activity
Number of subjects: 1206
Study 7721516 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate level of physical activity
Number of subjects: 1206
Study 7721516 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level of physical activity
Number of subjects: 1206
Study 7721516 — intervention group
Group type: COMPARATOR
Intervention: Physical activity
Number of subjects: 1206
Study 2915410 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl citrate (75 micrograms/h)
Number of subjects: 42
Study 2915410 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl citrate
Number of subjects: 42
Study 2915410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 1069608 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin alone
Number of subjects: 66
Study 1069608 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of daunorubicin, cytosine arabinoside, 6-thioguanine, and pyrimethamine
Number of subjects: 66
Study 31221165 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-arm trial designs with varying antibiotic treatment durations
Number of subjects: 0
Study 31221165 — intervention group
Group type: COMPARATOR
Intervention: Traditional head-to-head comparisons of limited numbers of durations
Number of subjects: 0
Study 28094141 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg intravenous zanamivir
Number of subjects: 626
Study 28094141 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg intravenous zanamivir
Number of subjects: 626
Study 28094141 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir (75 mg oral, twice a day)
Number of subjects: 626
Study 25108573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (enhanced dietary energy and protein)
Number of subjects: 165
Study 25108573 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 165
Study 23893223 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification coaching program (8-week telecoaching session following face-to-face education)
Number of subjects: 61
Study 23893223 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification coaching program
Number of subjects: 61
Study 23893223 — intervention group
Group type: COMPARATOR
Intervention: Control group (face-to-face education only)
Number of subjects: 61
Study 21525686 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml of 2% lidocaine HCl with 1:80,000 epinephrine injected into the buccal vestibule
Number of subjects: 75
Study 21525686 — intervention group
Group type: COMPARATOR
Intervention: Palatal injection
Number of subjects: 75
Study 18053047 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,550‐nm diode‐pumped erbium fiber laser (Fraxel SR, Reliant Technologies)
Number of subjects: 10
Study 16529799 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental stress (Trier Social Stress Test)
Number of subjects: 32
Study 16529799 — intervention group
Group type: COMPARATOR
Intervention: Non-stress procedure
Number of subjects: 32
Study 12972684 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus aerobic dance (DA)
Number of subjects: 90
Study 12972684 — intervention group
Group type: COMPARATOR
Intervention: Diet only (DO)
Number of subjects: 90
Study 12972684 — intervention group
Group type: COMPARATOR
Intervention: Diet plus walking (DW)
Number of subjects: 90
Study 11105340 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 205
Study 9101374 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (0.05 mg/day 17 beta‐estradiol) and calcium
Number of subjects: 90
Study 9101374 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 90
Study 9101374 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen in high bone turnover (HT) patients
Number of subjects: 90
Study 9101374 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen in low bone turnover (LT) patients
Number of subjects: 90
Study 1529687 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin‐like Growth Factor I (IGF I) plasma levels in children with Perthes' disease
Number of subjects: 59
Study 1529687 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth and weight measures in children with Perthes' disease
Number of subjects: 59
Study 1529687 — intervention group
Group type: COMPARATOR
Intervention: Insulin‐like Growth Factor I (IGF I) plasma levels in matched controls
Number of subjects: 59
Study 1529687 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of femoral head involvement according to Catterall (1971)
Number of subjects: 59
Study 3859166 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic tool based on clinical criteria
Number of subjects: 47
Study 3859166 — intervention group
Group type: COMPARATOR
Intervention: Non-eczematous controls
Number of subjects: 47
Study 31395020 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation intervention to increase uptake of evidence-based prevention of vascular disease
Number of subjects: 8
Study 31395020 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation intervention
Number of subjects: 8
Study 29099960 — intervention group
Group type: EXPERIMENTAL
Intervention: PNCA with a basal infusion
Number of subjects: 81
Study 29099960 — intervention group
Group type: EXPERIMENTAL
Intervention: PNCA without a basal infusion
Number of subjects: 81
Study 29099960 — intervention group
Group type: COMPARATOR
Intervention: IV PRN opioids
Number of subjects: 81
Study 29099960 — intervention group
Group type: EXPERIMENTAL
Intervention: PNCA (both with and without basal infusion)
Number of subjects: 81
Study 29099960 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 81
Study 27769879 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation practice (MMP)
Number of subjects: 36
Study 27769879 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness meditation description (MMD)
Number of subjects: 36
Study 24705678 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (3-month program)
Number of subjects: 21
Study 24705678 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 21985126 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track care programme (n = 40)
Number of subjects: 78
Study 25649195 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg/day)
Number of subjects: 50
Study 25649195 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (80 mg/day)
Number of subjects: 50
Study 17964037 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 20078
Study 17964037 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 20078
Study 15342049 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp-edged acrylic IOL (Sensar OptiEdge AR40e)
Number of subjects: 105
Study 15342049 — intervention group
Group type: COMPARATOR
Intervention: Round-edged acrylic IOL (AR40)
Number of subjects: 105
Study 15342049 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp-edged silicone IOL (ClariFlex OptiEdge)
Number of subjects: 105
Study 15342049 — intervention group
Group type: COMPARATOR
Intervention: Round-edged silicone IOL (PhacoFlex SI-40)
Number of subjects: 105
Study 11583720 — intervention group
Group type: EXPERIMENTAL
Intervention: colesevelam 3.8 g/day
Number of subjects: 94
Study 11583720 — intervention group
Group type: EXPERIMENTAL
Intervention: atorvastatin 10 mg/day
Number of subjects: 94
Study 11583720 — intervention group
Group type: EXPERIMENTAL
Intervention: coadministered colesevelam 3.8 g/day plus atorvastatin 10 mg/day
Number of subjects: 94
Study 11583720 — intervention group
Group type: EXPERIMENTAL
Intervention: atorvastatin 80 mg/day
Number of subjects: 94
Study 11583720 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 94
Study 9641933 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention with summary leaflet
Number of subjects: 636
Study 9641933 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention with Family Planning Association's leaflet
Number of subjects: 636
Study 9641933 — intervention group
Group type: EXPERIMENTAL
Intervention: Asking questions
Number of subjects: 636
Study 9641933 — intervention group
Group type: EXPERIMENTAL
Intervention: Asking questions in addition to summary leaflet
Number of subjects: 636
Study 9641933 — intervention group
Group type: EXPERIMENTAL
Intervention: Asking questions in addition to Family Planning Association leaflet
Number of subjects: 636
Study 9641933 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 636
Study 8018463 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin (0.4 ml)
Number of subjects: 12
Study 8018463 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.4 ml)
Number of subjects: 12
Study 8018463 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 12
Study 2680995 — intervention group
Group type: EXPERIMENTAL
Intervention: L-lactate
Number of subjects: 0
Study 2680995 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate
Number of subjects: 0
Study 2680995 — intervention group
Group type: COMPARATOR
Intervention: Acetate
Number of subjects: 0
Study 1187953 — intervention group
Group type: EXPERIMENTAL
Intervention: N-desmethyldiazepam
Number of subjects: 6
Study 1187953 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 6
Study 1187953 — intervention group
Group type: COMPARATOR
Intervention: N-desmethyldiazepam and Diazepam
Number of subjects: 6
Study 30770436 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time feedback and brief coaching
Number of subjects: 298
Study 30770436 — intervention group
Group type: COMPARATOR
Intervention: Measurement-only (control)
Number of subjects: 298
Study 31865604 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 fractions of 4-6 Gy per fraction (3 fractions/week)
Number of subjects: 325
Study 31865604 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 consecutive daily fractions of 5-6 Gy
Number of subjects: 325
Study 31865604 — intervention group
Group type: EXPERIMENTAL
Intervention: Single fraction of 7 Gy
Number of subjects: 325
Study 31865604 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 325
Study 29759512 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 599
Study 29759512 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 599
Study 27059039 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 403
Study 27059039 — intervention group
Group type: COMPARATOR
Intervention: Air Insufflation (AI)
Number of subjects: 403
Study 24920349 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.2 µg/kg/min) administered for 6 h at 2-week intervals over 6 weeks
Number of subjects: 120
Study 24920349 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered for 6 h at 2-week intervals over 6 weeks
Number of subjects: 120
Study 24920349 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 120
Study 24920349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 24920349 — intervention group
Group type: COMPARATOR
Intervention: Levosimendan and Placebo
Number of subjects: 120
Study 22746016 — intervention group
Group type: EXPERIMENTAL
Intervention: L group (Landiolol)
Number of subjects: 24
Study 22746016 — intervention group
Group type: EXPERIMENTAL
Intervention: LO group (Landiolol + Olprinone)
Number of subjects: 24
Study 20097585 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy with compression stockings (15-20 mmHg worn during the day, for 3 weeks)
Number of subjects: 60
Study 20097585 — intervention group
Group type: COMPARATOR
Intervention: Foam sclerotherapy without compression
Number of subjects: 60
Study 17945300 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum-A toxin alone
Number of subjects: 23
Study 17945300 — intervention group
Group type: COMPARATOR
Intervention: Botulinum-A toxin with oxybutynin chloride (control group)
Number of subjects: 23
Study 16222918 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal multiple micronutrient supplements (MM), 6 days per week from early pregnancy to delivery.
Number of subjects: 570
Study 16222918 — intervention group
Group type: COMPARATOR
Intervention: Iron only (FE) supplements, 6 days per week from early pregnancy to delivery.
Number of subjects: 570
Study 16222918 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal multiple micronutrient supplements (MM) among overweight women.
Number of subjects: 570
Study 16222918 — intervention group
Group type: COMPARATOR
Intervention: Iron only (FE) supplements among non-overweight women.
Number of subjects: 570
Study 12010137 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 236
Study 12010137 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 236
Study 12010137 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 236
Study 12010137 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin
Number of subjects: 236
Study 12010137 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 236
Study 12010137 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with opportunistic infections
Number of subjects: 236
Study 12010137 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of patients with complications
Number of subjects: 236
Study 10510142 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine 50 mg
Number of subjects: 12
Study 10510142 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 2 mg
Number of subjects: 12
Study 8595789 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB) hydrochloride monotherapy
Number of subjects: 144
Study 8595789 — intervention group
Group type: COMPARATOR
Intervention: Tiagabine (TGB) hydrochloride monotherapy (high-dose)
Number of subjects: 144
Study 1720407 — intervention group
Group type: EXPERIMENTAL
Intervention: Preinduction regimen with low-dose methotrexate followed by CHOP-Bleo chemotherapy
Number of subjects: 98
Study 1720407 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy with CHOP-Bleo
Number of subjects: 98
Study 6784581 — intervention group
Group type: COMPARATOR
Intervention: Atropine 3 micrograms/kg
Number of subjects: 5
Study 6784581 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 6 micrograms/kg
Number of subjects: 5
Study 6784581 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 12 micrograms/kg
Number of subjects: 5
Study 6784581 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 24 micrograms/kg
Number of subjects: 5
Study 6784581 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 5
Study 31408870 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (Sufi music at low tempo)
Number of subjects: 70
Study 31408870 — intervention group
Group type: COMPARATOR
Intervention: Control (no music therapy)
Number of subjects: 70
Study 28578819 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based dexterity program (HOMEDEXT)
Number of subjects: 103
Study 28578819 — intervention group
Group type: COMPARATOR
Intervention: Thera-band program
Number of subjects: 103
Study 25539931 — intervention group
Group type: EXPERIMENTAL
Intervention: Midluteal (ML) phase after total sleep deprivation (TSD)
Number of subjects: 14
Study 25539931 — intervention group
Group type: COMPARATOR
Intervention: Early follicular (EF) phase after total sleep deprivation (TSD)
Number of subjects: 14
Study 24166760 — intervention group
Group type: COMPARATOR
Intervention: MC4‐NN2‐0453 (0.03-1.50 mg/kg single dose)
Number of subjects: 136
Study 24166760 — intervention group
Group type: COMPARATOR
Intervention: MC4‐NN2‐0453 (0.75-3.0 mg/day multiple doses)
Number of subjects: 136
Study 24166760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 22485050 — intervention group
Group type: EXPERIMENTAL
Intervention: ACWY‐TT
Number of subjects: 1247
Study 22485050 — intervention group
Group type: COMPARATOR
Intervention: MenPS
Number of subjects: 1247
Study 19919594 — intervention group
Group type: COMPARATOR
Intervention: Brief intervention only (single 90-minute session)
Number of subjects: 284
Study 19919594 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 sessions with alcohol focus
Number of subjects: 284
Study 19919594 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 sessions with depression focus
Number of subjects: 284
Study 19919594 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 sessions with integrated focus
Number of subjects: 284
Study 17853761 — intervention group
Group type: EXPERIMENTAL
Intervention: Xingnao Kaiqiao needling method
Number of subjects: 4377
Study 17853761 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4377
Study 15761214 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified milk fat (ModFat)
Number of subjects: 31
Study 15761214 — intervention group
Group type: COMPARATOR
Intervention: Regular milk fat (RegFat)
Number of subjects: 31
Study 15761214 — intervention group
Group type: COMPARATOR
Intervention: Soft margarine (Marg)
Number of subjects: 31
Study 12140141 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine 25 mg/m² intravenous bolus on days 1 and 8 plus cisplatin 100 mg/m² on day 1 every 4 weeks (VC)
Number of subjects: 247
Study 12140141 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C 8 mg/m² i.v. on day 1, vindesine 3 mg/m² i.v. on days 1, 8, 15 and 22, plus cisplatin 100 mg/m² on day 1 every 4 weeks (MVP)
Number of subjects: 247
Study 12140141 — intervention group
Group type: COMPARATOR
Intervention: MVP regimen
Number of subjects: 247
Study 12140141 — intervention group
Group type: EXPERIMENTAL
Intervention: VC regimen
Number of subjects: 247
Study 9698962 — intervention group
Group type: EXPERIMENTAL
Intervention: Trach‐Vent heat and moisture exchanger
Number of subjects: 10
Study 9698962 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerodyne humidifier
Number of subjects: 10
Study 9698962 — intervention group
Group type: COMPARATOR
Intervention: Nam 35 humidifier
Number of subjects: 10
Study 7796569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 600 mg for 1 year
Number of subjects: 18
Study 7796569 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 18
Study 2082305 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine 10 mg 4 times a day as needed
Number of subjects: 823
Study 2082305 — intervention group
Group type: COMPARATOR
Intervention: aspirin 650 mg 4 times a day as needed
Number of subjects: 823
Study 7264966 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing activity and spinal stretch reflex during falls
Number of subjects: 0
Study 30794568 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min of 1.98 mA anodal tDCS applied over the primary motor cortex (M1)
Number of subjects: 10
Study 30794568 — intervention group
Group type: COMPARATOR
Intervention: Sham-operated control
Number of subjects: 10
Study 28045335 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus erlotinib (Arm 2)
Number of subjects: 82
Study 28045335 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone (Arm 1)
Number of subjects: 82
Study 28045335 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus erlotinib (Arm 2) in KRAS-WT patients
Number of subjects: 82
Study 28045335 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone (Arm 1) in KRAS-WT patients
Number of subjects: 82
Study 28045335 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus erlotinib (Arm 2) in KRAS-mutated patients
Number of subjects: 82
Study 28045335 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone (Arm 1) in KRAS-mutated patients
Number of subjects: 82
Study 28045335 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus erlotinib (Arm 2) in left-sided KRAS-WT patients
Number of subjects: 82
Study 28045335 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus erlotinib (Arm 2) in right-sided KRAS-WT patients
Number of subjects: 82
Study 25448095 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-focused intervention (repeated contacts, education, individualized feedback, quality improvement incentives)
Number of subjects: 4093
Study 25448095 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-focused intervention
Number of subjects: 4093
Study 23415550 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative fixation of fractured ribs
Number of subjects: 0
Study 23415550 — intervention group
Group type: COMPARATOR
Intervention: Current best practice mechanical ventilator management (control group)
Number of subjects: 0
Study 17473118 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of ACP-103 (20-300 mg)
Number of subjects: 0
Study 17473118 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of ACP-103 (50-150 mg)
Number of subjects: 0
Study 17473118 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of ACP-103 (up to 300 mg)
Number of subjects: 0
Study 17473118 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of ACP-103 (up to 100 mg once daily for 14 days)
Number of subjects: 0